Developed to treat diabetes, drugs like Ozempic now help fight obesity. Scientists newly honoured for working on them recall ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company released a statement Monday highlighting the safety of its in-development obesity treatment compared with other ...

The province and Novo Nordisk are accepting proposals from organizations to address childhood obesity and chronic disease in ...

Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug ...

Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s ...

O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...

The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 10 unusual trades. Delving into the details, we found 70% of ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Route 92 Medical announced today that it added a $50 million extension to its oversubscribed Series F financing round.

Scientists have detected lipid biomarkers in children and teenagers with obesity that indicate an increased risk of developing type 2 diabetes, liver and heart disease as adults. A one-year lifestyle ...